In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis
Ceftazidime-avibactam (CZA) is employed for the treatment of infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP). Resistance to CZA is frequently linked to point mutations in the blaKPC. We conducted in vitro simulations of in vivo blaKPC mutations using CZA. Fo...
Saved in:
Main Authors: | Siquan Shen, Chengkang Tang, Weiwei Yang, Li Ding, Renru Han, Qingyu Shi, Yan Guo, Dandan Yin, Fupin Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Emerging Microbes and Infections |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2024.2356146 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae
by: Qingyu Shi, et al.
Published: (2024-12-01) -
Overexpression of KPC contributes to ceftazidime-avibactam heteroresistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae
by: Yitan Li, et al.
Published: (2024-12-01) -
Ceftazidime-avibactam treatment dilemma of bla KPC−2-containing Klebsiella pneumoniae due to the development of co-existence of mixed strains carrying bla KPC−2 or bla KPC−33 in lung transplant recipients
by: Zichen Lei, et al.
Published: (2024-11-01) -
Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study
by: Yu CH, et al.
Published: (2024-12-01) -
The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting
by: Shobana Selvaganesan, et al.
Published: (2024-12-01)